Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Five Prime Therapeutics (FPRX) PT Raised to $31 at BMO Capital
March 18, 2015 8:26 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $31.00 (from $28.00) ) after the reported 4Q14 operating results yesterday. The firm sees a data-rich year end ahead.
Birchenough notes pipeline highlights include: "initiation of a phase 1a/b study of... More
